Pediatric Atopic Dermatitis

Anticipated Updates in Pediatric AD Guidelines (AAD 2026 Release)

A comprehensive review of the upcoming AAD pediatric AD guidelines, anticipated to be published in 2026. This session will explore how the new guidance aligns—or diverges—from allergy society recommendations, particularly around JAK inhibitors, biologics, and immunosuppressants. Discussion will highlight practical implications for clinicians and identify ongoing gaps in treatment sequencing.

Prevention Strategies: Early-Life Moisturizers and Topical Care

Emerging data suggest a pivotal role for early skin barrier support in preventing atopic dermatitis and related comorbidities. This session examines the evolving evidence for moisturizer use in infancy, early topical interventions, and the ongoing debate surrounding prevention strategies.

Nonsteroidal Management in Young Children: Practical “Bread and Butter” Approaches

This case-based session focuses on practical, real-world approaches to managing pediatric AD with nonsteroidal options. Attendees will learn how to navigate recent updates in international guidelines and integrate new therapies into their treatment algorithms.

Systemics vs Biologics in Pediatric AD: Expert Debate

A lively, data-driven debate exploring the use of systemic therapies versus biologics in children with moderate-to-severe AD. Topics include comparative efficacy, long-term safety considerations (including JAK inhibitors), and emerging data on developmental and quality-of-life outcomes.

Adult Atopic Dermatitis

OX40 Pathway Updates: Clinical Data and Evolving Role in AD Management

This session reviews the latest evidence for OX40 pathway inhibitors, including trial results, potential patient populations, and evolving safety profiles. Faculty will discuss how these agents may fit within the broader therapeutic landscape and what data are still needed for clinical integration.

AD Within Type 2 Inflammation: Links to Other Dermatologic Disorders

An exploration of AD through the lens of Type 2 inflammation and its intersection with other dermatologic and systemic diseases. Topics include IL-4 vs IL-13 biology, predictors of super-response, and broader systemic benefits of Type 2 pathway modulation.

Medical Crossfire: Treatment Selection Across Oral, Biologic, and Topical Options

An interactive, case-based session featuring expert perspectives on treatment sequencing and selection. Through debate and audience participation, faculty will explore how to choose between oral, biologic, and topical agents in diverse patient scenarios.

Late-Stage Pipeline Review 

A forward-looking review of the most advanced agents in development for atopic dermatitis. The session will highlight late-stage oral, topical, and biologic therapies, and their potential to address remaining unmet needs across both adult and pediatric populations.

Comorbidities & Atopic Dermatitis

A dual-focus session examining AD’s relationship with systemic and dermatologic comorbidities. Topics include the impact of obesity and metabolic dysfunction, as well as shared immune mechanisms with asthma, EoE, vitiligo, and related inflammatory disorders.

Chronic Hand Eczema: Emerging Treatments and Clinical Updates

This case-based session will cover current challenges and evolving therapies in chronic hand eczema management. Attendees will gain insight into emerging agents, global perspectives, and practical strategies for optimizing outcomes in complex cases.

Skin in the Game: Clinical Case Challenge

Bring your most unique cases in AD to be selected for an oral review with world class faculty. This presentation is designed to highlight the complexities of managing AD in both the adult and pediatric settings. Selection based on image-based cases with interesting presentation or management elements, and each case should include a brief introduction and summary for presentation purposes.